Heron Therapeutics, Inc. (HRTX)
NASDAQ$2.48
Market Cap
$377.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
625 of 924
Rank in Industry
360 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
HRTX Insider Trading Activity
HRTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or …
Insider Activity of Heron Therapeutics, Inc.
Over the last 12 months, insiders at Heron Therapeutics, Inc. have bought $0 and sold $0 worth of Heron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Heron Therapeutics, Inc. have bought $3.69M and sold $187,403 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $27,250 was made by Forbes William P (EVP, Chief Development Officer) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Heron Therapeutics, Inc.
| 2023-11-17 | Forbes William P | EVP, Chief Development Officer | 25,000 0.0179% | $1.09 | $27,250 | +121.10% | ||
| 2023-11-16 | Collard Craig A | Chief Executive Officer | 150,000 0.1065% | $0.92 | $137,970 | +162.87% | ||
| 2023-11-16 | Duarte Ira | EVP, Chief Financial Officer | 85,000 0.0584% | $0.89 | $75,599 | +162.87% | ||
| 2023-11-16 | Forbes William P | EVP, Chief Development Officer | 50,000 0.0363% | $0.94 | $46,995 | +162.87% | ||
| 2023-07-21 | Morgan Adam | director | 2.49M 2.0703% | $1.37 | $3.41M | +61.59% | ||
| 2022-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 1,504 0.0015% | $4.76 | $7,154 | -38.95% | |
| 2021-12-21 | Sale | Christian Waage | director | 300 0.0003% | $9.73 | $2,920 | -56.73% | |
| 2021-12-21 | Sale | Johnson Craig A | director | 250 0.0002% | $9.73 | $2,432 | -56.73% | |
| 2021-09-21 | Sale | Christian Waage | director | 600 0.0006% | $12.31 | $7,384 | -54.08% | |
| 2021-09-21 | Sale | Johnson Craig A | director | 500 0.0005% | $12.30 | $6,148 | -54.08% | |
| 2021-06-21 | Sale | Christian Waage | director | 600 0.0006% | $15.20 | $9,118 | -40.10% | |
| 2021-06-21 | Sale | Johnson Craig A | director | 500 0.0005% | $15.20 | $7,601 | -40.10% | |
| 2021-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 3,058 0.0032% | $17.66 | $54,017 | -39.34% | |
| 2021-04-15 | Sale | Christian Waage | director | 600 0.0006% | $17.51 | $10,508 | -38.97% | |
| 2021-04-06 | Sale | Johnson Craig A | director | 500 0.0005% | $17.22 | $8,610 | -33.90% | |
| 2021-01-14 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 1,654 0.0018% | $18.09 | $29,920 | -29.12% | |
| 2021-01-08 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 7,142 0.0039% | $9.83 | $70,219 | -32.19% | |
| 2020-12-22 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 20,000 0.0176% | $16.50 | $330,000 | -32.95% | |
| 2020-05-01 | Sale | MANHARD KIMBERLY | Executive VP, Drug Development | 2,316 0.0013% | $6.98 | $16,176 | +25.16% | |
| 2019-11-29 | Sale | MANHARD KIMBERLY | Executive VP, Drug Development | 48,000 0.0274% | $13.00 | $624,000 | -35.68% |
Total: 115
Insider Historical Profitability
18.13%
| Morgan Adam | director | 6986744 4.5866% | $17.33M | 1 | 0 | +61.59% |
| TANG KEVIN C | director | 5799810 3.8074% | $14.38M | 19 | 1 | +4.62% |
| Collard Craig A | Chief Executive Officer | 186496 0.1224% | $462,510.08 | 1 | 0 | +162.87% |
| RIEPENHAUSEN PETER | director | 179332 0.1177% | $444,743.36 | 2 | 0 | |
| Quart Barry D | Chief Executive Officer | 94652 0.0621% | $234,736.96 | 3 | 4 | <0.0001% |
Historical Insider Profitability vs. Competitors
$84,871,118 | 57 | 17.71% | $397.96M | |
Heron Therapeutics, Inc. (HRTX) | $109,415,500 | 33 | 18.13% | $377.78M |
$73,222,926 | 18 | 60.19% | $393.24M | |
$14,865,077 | 18 | -28.56% | $392.27M | |
$49,750,490 | 17 | 37.19% | $385.79M |
HRTX Institutional Investors: Active Positions
| Increased Positions | 69 | +31.94% | 8M | +6.9% |
| Decreased Positions | 86 | -39.81% | 15M | -12.45% |
| New Positions | 25 | New | 5M | New |
| Sold Out Positions | 37 | Sold Out | 6M | Sold Out |
| Total Postitions | 199 | -7.87% | 115M | -5.54% |
HRTX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rubric Capital Management Lp | $61,975.00 | 17.58% | 26.71M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $19,931.00 | 5.65% | 8.59M | +56,175 | +0.66% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $19,720.00 | 5.59% | 8.5M | -350,000 | -3.96% | 2024-12-31 |
| Vanguard Group Inc | $18,926.00 | 5.37% | 8.16M | -562,567 | -6.45% | 2024-12-31 |
| Velan Capital Investment Management Lp | $16,209.00 | 4.6% | 6.99M | 0 | 0% | 2024-12-31 |
| Tejara Capital Ltd | $10,815.00 | 3.07% | 4.66M | -644,269 | -12.14% | 2024-12-31 |
| Palisade Capital Management, Lp | $9,109.00 | 2.58% | 3.93M | -65,889 | -1.65% | 2024-12-31 |
| D. E. Shaw & Co., Inc. | $8,639.00 | 2.45% | 3.72M | -660,971 | -15.07% | 2024-12-31 |
| State Street Corp | $7,299.00 | 2.07% | 3.15M | -46,243 | -1.45% | 2024-12-31 |
| Point72 Asset Management, L.P. | $7,136.00 | 2.02% | 3.08M | +3M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.